Submitted by jaj2026 on October 27, 2017 - 4:20pm
Title | Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Jones GH, Carrier MA, Silver RT, Kantarjian H |
Journal | Blood |
Volume | 127 |
Issue | 11 |
Pagination | 1398-402 |
Date Published | 2016 Mar 17 |
ISSN | 1528-0020 |
Keywords | Antitrust Laws, Drug Approval, Drug Costs, Drug Industry, Drug Substitution, Drugs, Generic, Economic Competition, Global Health, Insurance, Pharmaceutical Services, Lobbying, Patents as Topic, Prescription Fees, Therapeutic Equivalency, United States, United States Food and Drug Administration |
Abstract | High cancer drug prices are influenced by the availability of generic cancer drugs in a timely manner. Several strategies have been used to delay the availability of affordable generic drugs into the United States and world markets. These include reverse payment or pay-for-delay patent settlements, authorized generics, product hopping, lobbying against cross-border drug importation, buying out the competition, and others. In this forum, we detail these strategies and how they can be prevented. |
DOI | 10.1182/blood-2015-11-680058 |
Alternate Journal | Blood |
PubMed ID | 26817958 |
PubMed Central ID | PMC4915805 |